TRCT
AVBP icon

Tower Research Capital (TRC)’s ArriVent BioPharma AVBP Stock Holding History

Tower Research Capital (TRC)’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.2K Sell
1,559
-941
-38% -$27.8K ﹤0.01% 2662
2026
Q1 		$57.7K Buy
2,500
+130
+5% +$2.94K ﹤0.01% 2615
2025
Q4 		$47.7K Buy
2,370
+1,087
+85% +$22.6K ﹤0.01% 2455
2025
Q3 		$23.7K Sell
1,283
-5,386
-81% -$106K ﹤0.01% 3153
2025
Q2 		$145K Buy
6,669
+5,676
+572% +$118K ﹤0.01% 2075
2025
Q1 		$18.4K Sell
993
-606
-38% -$14.8K ﹤0.01% 3048
2024
Q4 		$42.6K Buy
1,599
+1,416
+774% +$40.7K ﹤0.01% 2655
2024
Q3 		$4.3K Sell
183
-1,309
-88% -$29.7K ﹤0.01% 4597
2024
Q2 		$27.7K Buy
1,492
+888
+147% +$15.8K ﹤0.01% 3549
2024
Q1 		$10.8K Buy
+604
New +$12.2K ﹤0.01% 3651

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Tower Research Capital (TRC)'s AVBP Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its ArriVent BioPharma (AVBP) stake by 38% in Q2 2026, selling an estimated $27.8K and leaving 1,559 shares worth $54.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2662.

Tower Research Capital (TRC) first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. The position peaked at $145K in Q2 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Tower Research Capital (TRC) held 1,559 shares of ArriVent BioPharma worth $54.2K as of Q2 2026.
  • Tower Research Capital (TRC) sold 941 ArriVent BioPharma shares in Q2 2026, an estimated $27.8K.
  • ArriVent BioPharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2662 holding.
  • Tower Research Capital (TRC) first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • Tower Research Capital (TRC)'s ArriVent BioPharma position peaked at $145K in Q2 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.